...
首页> 外文期刊>Clinical therapeutics >A randomized, double-blind, 8-week crossover study of once-daily controlled-release tramadol versus immediate-release tramadol taken as needed for chronic noncancer pain.
【24h】

A randomized, double-blind, 8-week crossover study of once-daily controlled-release tramadol versus immediate-release tramadol taken as needed for chronic noncancer pain.

机译:根据慢性非癌性疼痛的需要,对每日一次的控释曲马多与即释曲马多进行了一项随机,双盲,为期8周的交叉研究。

获取原文
获取原文并翻译 | 示例

摘要

OBJECTIVE:: The purpose of this study was to evaluate the efficacy of controlled-release (CR) tramadol and immediate-release (IR) tramadol in patients with moderate or greater intensity chronic noncancer pain. METHODS:: A total of 122 patients underwent washout from all opioids 2 to 7 days before randomization to 1 of 2 groups: active CR tramadol 200 mg every morning plus placebo IR tramadol 50 mg every 4 to 6 hours PRN rescue, or placebo CR tramadol 200 mg every morning plus active IR tramadol 50 mg every 4 to 6 hours PRN rescue. After 2 weeks, the doses were increased to CR tramadol 400 mg or placebo and IR tramadol 100 mg every 4 to 6 hours PRN or placebo, as rescue. After 4 weeks in the first phase, patients crossed over to the alternative treatment for another 4 weeks. Pain intensity (100-mm visual analog scale [VAS] and 5-point ordinal scales) was assessed twice daily in diaries. Pain intensity, Pain and Disability Index (PDI; 0-10 ordinal scale), Pain and Sleep Questionnaire (100-mm VAS), and analgesic effectiveness (7-point ordinal scale) were assessed at biweekly clinic visits. RESULTS:: Sixty-five patients (35 men, 30 women) completed the study. Mean (SD) age was 56.5 (12.7) years; mean (SD) weight was 82.0 (18.5) kg. Daily diary pain intensity (mean [SD]) was significantly lower in the CR tramadol group than in the IR tramadol group in the last 2 weeks of each phase (completers: VAS, 29.9 [20.5] vs 36.2 [20.4] mm, P < 0.001; ordinal scale, 1.41 [0.7] vs 1.64 [0.6], P < 0.001; intent-to-treat [ITT] population: VAS, 32.5 [22.9] vs 38.6 [21.2] mm, P < 0.003; ordinal scale, 1.50 [0.8] vs 1.72 [0.7], P < 0.002). The overall pain intensity scores from the daily diary were also significantly better with CR tramadol for both the completers and ITT. Similar results were obtained on the biweekly VAS pain intensity questionnaire. No differences were found between treatments in total PDI or overall Pain and Sleep scores in either population. For the completers, both patients and investigators rated effectiveness higher for CR tramadol than for IR tramadol (P < 0.004 and P < 0.008 for patients and investigators, respectively). CONCLUSION:: This study reports significant improvement in pain intensity with CR tramadol as compared with IR tramadol.
机译:目的:本研究的目的是评估缓释曲马多和速释曲马多对中度或重度慢性非癌性疼痛患者的疗效。方法:总共122名患者在随机分为2组中的1组之前的2至7天接受了所有阿片类药物的冲洗:每天2个月服用活性CR曲马多200 mg,每4至6小时安慰剂IR曲马多50 mg PRN抢救,或安慰剂CR曲马多每天200毫克,再加上活跃的IR曲马多,每4至6小时PRN抢救50毫克。 2周后,每4至6小时PRN或安慰剂将剂量增加至CR曲马多400 mg或安慰剂和IR曲马多100 mg,以进行急救。在第一阶段4周后,患者又接受了替代治疗4周。每天在日记中评估疼痛强度(100毫米视觉模拟量表[VAS]和5点序数表)。在每两周一次的门诊就诊时评估疼痛强度,疼痛和残疾指数(PDI; 0-10等级量表),疼痛和睡眠问卷(100毫米VAS)和镇痛效果(7点等级量表)。结果:65名患者(35名男性,30名女性)完成了研究。平均(SD)年龄为56.5(12.7)岁;平均(SD)重量为82.0(18.5)公斤。在每个阶段的最后两周,CR曲马多组的每日日记疼痛强度(均值[SD])明显低于IR曲马多组(完成者:VAS,29.9 [20.5] vs 36.2 [20.4] mm,P < 0.001;顺序量表,1.41 [0.7]和1.64 [0.6],P <0.001;意向治疗[ITT]人群:VAS,32.5 [22.9]和38.6 [21.2] mm,P <0.003;顺序量表,1.50 [0.8]对1.72 [0.7],P <0.002)。 CR曲马多对完成人和ITT的每日日记总的疼痛强度评分也显着提高。在每两周一次的VAS疼痛强度调查表上获得了类似的结果。两种人群的总PDI或总体疼痛和睡眠评分在治疗之间均未发现差异。对于完成者,CR和曲马多的疗效均高于IR和曲马多(对于患者和研究人员,P <0.004和P <0.008)。结论:该研究报告说,CR曲马多的疼痛强度与IR曲马多相比有显着改善。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号